Zhang-James, Yanli
Fernàndez-Castillo, Noèlia
Hess, Jonathan L
Malki, Karim
Glatt, Stephen J
Cormand, Bru http://orcid.org/0000-0001-5318-4382
Faraone, Stephen V http://orcid.org/0000-0002-9217-3982
Article History
Received: 1 August 2017
Revised: 4 March 2018
Accepted: 3 April 2018
First Online: 1 June 2018
Compliance with ethical standards
:
: In the past year, S.V.F. received income, travel expenses, and/or research support from and/or has been on an Advisory Board for Pfizer, Ironshore, Shire, Akili Interactive Labs, CogCubed, Alcobra, VAYA Pharma, Neurovance, Impax, NeuroLifeSciences, and research support from the National Institutes of Health (NIH). With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. S.V.F. receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i>, Oxford University Press: <i>Schizophrenia: The Facts</i>, and Elsevier: <i>ADHD: Non-Pharmacologic Treatments</i>. During the past year, K.M. received income from and has been an employee and stockholder of Eli Lilly and UCB Celltech. The remaining authors declare that they have no conflict of interest.